TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms - PubMed (original) (raw)
Comparative Study
. 1997 Nov-Dec;17(6D):4473-8.
Affiliations
- PMID: 9494553
Comparative Study
TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms
A Harłozinska et al. Anticancer Res. 1997 Nov-Dec.
Abstract
The serum markers TPS and CA 125 were determined in serum, cyst fluid and ascites in ovarian carcinoma patients and in patients with benign ovarian neoplasms. The levels of TPS and CA 125 were significantly higher in malignant and benign tumor cysts and ascitic fluids than in corresponding patients sera (p < 0.005 for TPS, p < 0.0001 for CA 125). The concentrations of cyst fluid TPS and CA 125 were also usually higher in cancer patients than in patients with benign ovarian neoplasms. TPS and CA 125 were elevated in a higher proportion of ovarian cancer patients sera than in benign ovarian patients' sera (p < 0.001 for both markers). Serum preoperative TPS and CA 125 levels were significantly higher in patients with advanced disease (FIGO stage III/IV) than in patients with early stage disease (FIGO stage I/II, p = 0.002, p < 0.05 respectively). When histology was considered, small differences in the marker signals were noted for TPS and CA 125 with the exception of mucinous neoplasms, where TPS showed a markedly higher signal. These results suggest that the combined use of TPS and CA 125 could be of additive value for the identification of epithelial ovarian neoplasms. Postsurgical TPS sera levels achieved the normal values faster than CA 125 suggesting that determination of TPS concentration before and 3 days after surgery seems to be valuable for the evaluation of radical surgery.
Similar articles
- Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P, Frydecka I, Gabryś M, Van Dalen A, Einarsson R, Harłozińska A. Sedlaczek P, et al. Cancer. 2002 Nov 1;95(9):1886-93. doi: 10.1002/cncr.10917. Cancer. 2002. PMID: 12404282 - CA 125 and carcinoembryonic antigen levels in cyst fluid, ascites and serum of patients with ovarian neoplasms.
Harłozińska A, Bar JK, Gawlikowski W, Richter R, Cisło M. Harłozińska A, et al. Ann Chir Gynaecol. 1991;80(4):368-75. Ann Chir Gynaecol. 1991. PMID: 1667567 - Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients.
van Dalen A, Favier J, Burges A, Hasholzner U, de Bruijn HW, Dobler-Girdziunaite D, Dombi VH, Fink D, Giai M, McGing P, Harlozinska A, Kainz C, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R. van Dalen A, et al. Gynecol Oncol. 2000 Dec;79(3):444-50. doi: 10.1006/gyno.2000.5982. Gynecol Oncol. 2000. PMID: 11104617 Clinical Trial. - Coexistence of struma ovarii with marked ascites and elevated CA-125 levels: case report and literature review.
Mui MP, Tam KF, Tam FK, Ngan HY. Mui MP, et al. Arch Gynecol Obstet. 2009 May;279(5):753-7. doi: 10.1007/s00404-008-0794-1. Epub 2008 Sep 20. Arch Gynecol Obstet. 2009. PMID: 18807056 Review. - [Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)].
Göcze P, Vahrson H. Göcze P, et al. Orv Hetil. 1993 Apr 25;134(17):915-8. Orv Hetil. 1993. PMID: 8479736 Review. Hungarian.
Cited by
- The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination.
Ritch SJ, Telleria CM. Ritch SJ, et al. Front Endocrinol (Lausanne). 2022 Apr 28;13:886533. doi: 10.3389/fendo.2022.886533. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35574025 Free PMC article. Review. - The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors.
Baci D, Bosi A, Gallazzi M, Rizzi M, Noonan DM, Poggi A, Bruno A, Mortara L. Baci D, et al. Int J Mol Sci. 2020 Apr 28;21(9):3125. doi: 10.3390/ijms21093125. Int J Mol Sci. 2020. PMID: 32354198 Free PMC article. Review. - Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125).
Belisle JA, Gubbels JA, Raphael CA, Migneault M, Rancourt C, Connor JP, Patankar MS. Belisle JA, et al. Immunology. 2007 Nov;122(3):418-29. doi: 10.1111/j.1365-2567.2007.02660.x. Epub 2007 Jul 6. Immunology. 2007. PMID: 17617155 Free PMC article. - Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.
Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, Bera TK, Connor J, Sathyanarayana BK, Lee B, Pastan I, Patankar MS. Gubbels JA, et al. Mol Cancer. 2006 Oct 26;5(1):50. doi: 10.1186/1476-4598-5-50. Mol Cancer. 2006. PMID: 17067392 Free PMC article. - Influence of tumor grade on expression of CA 125 in serum and tissue in patients with serous ovarian carcinoma.
But I. But I. Wien Klin Wochenschr. 2003 Apr 30;115(7-8):255-8. doi: 10.1007/BF03040324. Wien Klin Wochenschr. 2003. PMID: 12778778
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials